Background: The Vicious Cycle of Hypertension and Kidney Disease
Chronic kidney disease (CKD) and hypertension often fuel each other in a dangerous cycle: high blood pressure worsens kidney damage, and declining kidney function further elevates blood pressure. Many patients remain uncontrolled despite standard therapies such as ACE inhibitors or ARBs, significantly increasing risks of heart attack, stroke, heart failure, and kidney failure.
How Baxdrostat Works
Baxdrostat is an aldosterone synthase inhibitor, a novel class that directly reduces the body's production of aldosterone. Produced by the adrenal glands, aldosterone regulates salt and water balance. Excess aldosterone causes sodium and water retention, raising blood pressure; it also damages blood vessels, promotes cardiovascular stiffening, and accelerates kidney scarring.
Clinical Trial Results
The 26-week Phase 2 trial enrolled 195 patients with CKD and uncontrolled hypertension. At baseline, average systolic blood pressure was 151 mmHg, urine albumin was 714 mg/g creatinine (normal <30), and eGFR was 44 mL/min/1.73 m².
- Blood pressure reduction: Baxdrostat lowered systolic BP by an additional 8.1 mmHg (about 5%) compared to placebo.
- Kidney protection: Urine albumin levels dropped 55% versus placebo, comparable to known kidney-protective medications.
- Safety: Hyperkalemia (high potassium) was more common with baxdrostat (41% vs. 5%), mostly mild to moderate. No deaths or unexpected adverse events occurred.
Expert Commentary
Lead author Dr. Jamie P. Dwyer from University of Utah Health stated, 'These findings are encouraging for people living with CKD and hypertension, two conditions that often go hand-in-hand and create a dangerous cycle.' Dr. Jordana B. Cohen from the University of Pennsylvania, who was not involved in the study, added, 'This medication class could be a game changer in the management of hypertension in this patient group.'
What's Next
The Phase 3 BaxHTN trial, presented at ESC 2025, confirmed that 2 mg baxdrostat reduced seated systolic BP by 15.7 mmHg from baseline (9.8 mmHg placebo-adjusted). Two large Phase 3 studies are now testing whether baxdrostat can delay CKD progression.